HIP1 Activators
The activators listed above target various cellular mechanisms and signaling pathways that can indirectly influence the activity of HIP1. HIP1's role in clathrin-mediated endocytosis and interaction with cytoskeletal components makes it sensitive to changes in these cellular processes. Dynasore, by inhibiting dynamin, impacts endocytosis, which is a critical pathway for HIP1. Similarly, PI3K inhibitors like LY294002 and Wortmannin can alter endocytic trafficking, which is significant given HIP1's involvement in this process. The modulation of PKC activity through agents like PMA may also indirectly affect HIP1, considering the broad influence of PKC on cellular signaling.
Furthermore, the role of HIP1 in intracellular trafficking and cytoskeletal dynamics is highlighted by the potential impact of microtubule destabilizing agents like Nocodazole and actin polymerization inhibitors such as Cytochalasin D. The influence of HDAC inhibitors (e.g., Vorinostat) and HSP90 inhibitors (e.g., 17-AAG) points towards the significance of protein expression regulation and stability in HIP1 activity. Rapamycin, an autophagy modulator, and Bortezomib, a proteasome inhibitor, represent compounds that influence cellular degradation pathways, further emphasizing the complexity of HIP1's functional network.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, can affect endocytic trafficking, potentially influencing HIP1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, altering endocytic pathways and potentially affecting HIP1. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator that might influence HIP1 function through modulating signaling pathways. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
As a calcium channel blocker, Nifedipine can affect intracellular signaling, potentially modulating HIP1 activity. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole, a microtubule destabilizing agent, might influence HIP1 activity due to its interaction with the cytoskeleton. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
This compound inhibits actin polymerization and could indirectly modulate HIP1 function. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat, an HDAC inhibitor, can alter gene expression patterns, potentially affecting HIP1's function or expression. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
An HSP90 inhibitor, 17-AAG might impact protein folding and stability, affecting HIP1-associated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an autophagy modulator, might indirectly influence HIP1 activity through its role in cellular degradation processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
As a proteasome inhibitor, Bortezomib can affect cellular protein degradation pathways, potentially impacting HIP1 function. | ||||||